The need for validating the use of tumor markers was demonstrated in the recent evaluation of cancer antigen 125
(CA125) (2) measurements for monitoring patients with ovarian cancer (2).
The correct primary diagnosis code for this situation is 795.82 (elevated cancer antigen 125
), followed by V16.41 (family history of malignant neoplasm; genital organs; ovary).
Cancer antigen 125
(CA-125)  is the tumor marker of choice in ovarian cancer (2, 4-6).
After this initial study, we had some biomarker candidates that, in conjunction with cancer antigen 125
(CA125),  appeared to provide a modest improvement over CA125 alone for the detection of early-stage ovarian cancer.
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125
(CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Tumor markers, such as [alpha]-fetoprotein (AFP) , carcinoembryonic antigen (CEA), cancer antigen 125
(CA 125), and CA 15-3, can be found in the body (usually blood or urine) when cancer is present (1).
Cancer antigen 125
(CA 125) (1-3) is commonly increased in liver cirrhosis and increased even more in ascitic fluid (4-6).
During the last 10 years, tumor marker assays for human chorionic gonadotropin (hCG), prostate-specific antigen (PSA), cancer antigen 125
(CA 125), carcinoembryonic antigen, and calcitonin have all been reported to suffer from this problem, frequently with undesirable clinical outcomes (3-7).
Interpretation of sequential measurements of cancer antigen 125
(CA 125) Carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer.
Placental alkaline phosphatase and cancer antigen 125
in sera of patients with benign and malignant diseases.
Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125
(CA125) in patients with epithelial ovarian cancer.
The value of cancer antigen 125
(CA 125) during treatment and follow-up of patients with ovarian cancer.